EUR 0.36
(0.42%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -10.51 Million EUR | -45.43% |
2022 | -6.88 Million EUR | 16.6% |
2021 | -8.06 Million EUR | -6.73% |
2020 | -4.83 Million EUR | 44.52% |
2019 | -6.32 Million EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | -2.01 Million EUR | 0.0% |
2024 Q1 | -2.01 Million EUR | 26.42% |
2023 Q4 | -2.73 Million EUR | 0.0% |
2023 FY | - EUR | -45.43% |
2023 Q3 | -2.73 Million EUR | -23.17% |
2023 Q2 | -2.22 Million EUR | 0.0% |
2023 Q1 | -2.22 Million EUR | -11.6% |
2022 FY | - EUR | 16.6% |
2022 Q4 | -1.99 Million EUR | 0.0% |
2021 FY | - EUR | -6.73% |
2020 FY | - EUR | 44.52% |
2019 FY | - EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Nicox S.A. | -16.23 Million EUR | 35.275% |
European Medical Solutions | 59 Thousand EUR | 17913.559% |
PHAXIAM Therapeutics S.A. | -22.93 Million EUR | 54.165% |